LakeShore Biopharma Co Ltd
LSB0.627USD
-0.163-20.68%
收盘 09/19, 16:00（美东）报价延迟15分钟
13.02M总市值
--市盈率 TTM
关于 LakeShore Biopharma Co Ltd 公司
LakeShore Biopharma Co Ltd（原名 YS Biopharma Co Ltd）是一家生物制药公司，致力于发现、开发、生产和商业化新一代传染病和癌症疫苗和治疗性生物制剂。公司的疫苗产品 YSJATM 狂犬病疫苗已实现商业化。公司还有四种处于不同临床开发阶段的候选产品，包括 PIKA 狂犬病疫苗、PIKA 重组 COVID-19 疫苗、PIKA YS-ON-001 和 PIKA YS-HBV-001，以及四种临床前阶段的候选产品，针对具有巨大医疗需求的 HBV、流感和癌症。此外，公司正在研究一系列处于发现阶段的治疗靶点、狂犬病和产品。
公司简介
公司代码LSB
公司名称LakeShore Biopharma Co Ltd
上市日期Jul 30, 2021
CEOMr. Dave Chenn
员工数量573
证券类型Ordinary Share
年结日Jul 30
公司地址Building No. 2, 38 Yongda Road
城市BEIJING
上市交易所NASDAQ Capital Market Consolidated
国家China
邮编102629
电话
网址https://www.ysbiopharm.com/
公司代码LSB
上市日期Jul 30, 2021
CEOMr. Dave Chenn
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
其他
12.17%
持股股东
持股股东
占比
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
其他
12.17%
股东类型
持股股东
占比
Corporation
74.87%
Individual Investor
12.67%
Investment Advisor
0.36%
Investment Advisor/Hedge Fund
0.26%
Private Equity
0.13%
Hedge Fund
0.04%
其他
11.67%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
28
16.97M
69.54%
+11.06M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.59K
0.06%
+10.59K
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
公告日期
类型
比率
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
